Cape Fear BioCapital closes Fund I to back North Carolina biotech startups
What's the deal? Cape Fear BioCapitalDealroom has a profile for this one. Try Dealroom → has announced the final close of Fund I, an expanded vehicle to invest in early-stage therapeutics companies in North Carolina. The fund is anchored by Moore Strategic Ventures, the investment company of Louis M. Bacon, and backed by strategic partners including Parexel and a group of state operators, founders, and executives.
What's the endgame? The firm writes first institutional cheques and builds companies hands-on at the earliest stage. Since launching in late 2024, it has made seven investments from more than 200 opportunities, and the expanded fund adds capacity for three to five more startups.
Why now? In June 2026, Cape Fear partnered with Parexel to launch the Parexel Biotech Incubator, connecting early-stage companies with clinical and regulatory development expertise. The new limited partners bring operating experience alongside capital.
Among them is Brendan Griffin, who led Propella Therapeutics through its $175M acquisition by Astellas Pharma in 2023. "I invested with Cape Fear to contribute both capital and my operating experience to our most promising startups so they can grow here," he said.
What could go wrong? The firm's thesis is concentrated in a single state and sector, tying its returns to North Carolina's biotech pipeline. Early portfolio momentum has yet to translate into exits.
General partner Ed Field framed the gap the firm set out to fill. "When we launched, we said North Carolina had everything it needed to build world-class biotech companies except access to early capital and the operators who've done it before," he said.
The signal: Cape Fear is betting that regional science and talent can be developed into globally competitive companies without leaving the state. It aims to invest in and launch more than 40 seed-stage companies in North Carolina during its first decade, with a second, larger fund already in view.
Read more: Business Insider
Image credit: Generated with Gemini
